Medicines Law & Policy responds to US Health and Human Services Department request for...

On 12 December 2023 the US Health and Human Services Department (HHS) posted a notice and request for comments on “the implications of access...

A better way to solve a crisis: A new mechanism for incentivising R&D on...

Antimicrobial resistance is the ‘silent’ pandemic: Globally, it costs 5 million lives a year, and is set to rise to more than 8 million...

Decision on intellectual property waiver over Covid technology on hold till 2021; what are...

Note: This article was edited on 19 December to include a statement from the EU supporting sharing of intellectual property, technology, and know-how transfer. The...

The Waiver that Wasn’t: Is the pharma lobby responsible?

Systemic lobbying pressure from pharmaceutical companies – allegedly attached to threats to withdraw investments – may have been responsible for the watering down of...

The Role of Activism in Shaping Law and Policies that Support Access to Medicines

This article is also available as a PDF here. Almost 26 years ago, here in Amsterdam, on November 25-26, 1999, Health Action International, Médecins Sans...

Cystic Fibrosis Medicines Wars in Europe

Monday 4 February, the UK parliament will debate the issuing of a compulsory licence by the government, called ‘Crown use’, for the cystic fibrosis...

The European Commission’s proposal on a new EU-wide compulsory licensing regime

Guest author Olga Gurgula is a Senior Lecturer in Intellectual Property Law at Brunel Law School, Brunel University London A recent international health emergency, the...

Advanced Purchase Agreements for Covid-19 Vaccines: Do they ensure Global Public Good?

Advanced Purchase Agreements (APAs) were part of a strategy to provide upfront financing for Covid-19 vaccines and to accelerate their development and availability. Since...

European Commission Publishes Expert Panel’s Recommendations on High Drug Prices

This month the European Commission published Innovative Payment Models for High-Cost Innovative Medicines, a report of the Expert Panel on effective ways of investing...

World Trade Organization Members Embark on Review of the TRIPS Agreement

The World Trade Organization (WTO) Trade-Related Aspects of Intellectual Property Rights (TRIPS) Council will meet on 10-11 July. On the agenda is the review...